Results 281 to 290 of about 146,874 (392)

A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease [PDF]

, 2006
Paola Papaldo, Alessandra Fabi, G. Ferretti, Marcella Mottolese, Anna Maria Cianciulli, Barbara Di Cocco, Maria Simona Pino, Paolo Carlini, Serena Di Cosimo, I Sacchi, Isabella Sperduti, C. Nardoni, F. Cognetti   +12 more
openalex   +1 more source

Preirradiation of Spheroids with ²²⁵Ac-Trastuzumab Improves Penetration of ²²⁵Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails. [PDF]

J Nucl Med
Tallam H, Nair R, Sarkar A, Katugampola S, Sofou S, Howell RW.   +5 more
europepmc   +1 more source

µMap Photoproximity Labeling on the Cell Surface

Current Protocols, Volume 5, Issue 10, October 2025.
Abstract Understanding a protein's interactome provides crucial insight into its function and its contribution to disease. Traditional methods such as co‐immunoprecipitations often fail to capture interactions that are dependent on native cellular architecture such as those found on the cellular membrane. While enzyme‐based proximity labeling utilizing
Hong Kai Ng, Cameron J. Douglas, Ciaran P. Seath   +2 more
wiley   +1 more source

Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: Local stimulation using magnetic microspheres as assessed by quantitative digital microscopy

, 2005
Elza Friedländer, Donna J. Arndt‐Jovin, Péter Nagy, Thomas M. Jovin, János Szöllősi, György Vereb   +5 more
openalex   +1 more source

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study [PDF]

, 2006
Carmelo Bengala, Claudio Zamagni, Paolo Pedrazzoli, Paola Matteucci, Alberto Ballestrero, G. Da Prada, Massimo Martino, Giovanni Rosti, Marco Danova, Marco Bregni, Gordana Jovic, Valentina Guarneri, M Maur, Pierfranco Conté   +13 more
openalex   +1 more source

A recurrence risk score model evaluating effects of postmastectomy radiotherapy in breast cancer patients with pathologically negative lymph nodes after neoadjuvant chemotherapy: a multicenter, retrospective study. [PDF]

Ther Adv Med Oncol
Wang DQ, Huang Z, Wu HF, Shen DX, Jing H, Fang H, Zhu L, Huang XB, Shen LF, Shi M, Chen JY, Liu M, Cheng J, Li YX, Tie J, Tang Y, Wang SL.   +16 more
europepmc   +1 more source

Trastuzumab halves risk of recurrence of breast cancer in some women

, 2005
Roger Dobson
openalex   +2 more sources

Mass spectrometric imaging and quantitative analysis of the <i>in vivo</i> biodistribution of trastuzumab using a rhodium(iii) sarcophagine complex.

Inorg Chem Front
Patel N, Pham TT, Banu A, Griffiths A, Paterson BM, Firth G, Morrell A, McMahon C, Long NJ, Baker JR, Chudasama V, Ma MT.   +11 more
europepmc   +1 more source

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients

International Journal of Cancer, Volume 157, Issue 7, Page 1465-1480, 1 October 2025.
What's New? Circulating tumor cells can offer insights into treatment responses and metastatic recurrence, but current analysis methods are limited. Here, the authors tested a newly developed mass cytometry panel comprising biomarkers such as γH2AX and RAD51 in longitudinally monitored metastatic breast cancer patients.
Kathrin Niedermayer, Henning Schäffler, Georgios Vlachos, Sara Greco, Kerstin Pfister, Barbara Volz, Leonie Ott, Hans Neubauer, Bernhard Polzer, André Koch, Sabine Riethdorf, Tanja Fehm, Wolfgang Janni, Thomas W. P. Friedl, Brigitte Rack, Ellen Heitzer, Fabienne Schochter, Lisa Wiesmüller   +17 more
wiley   +1 more source

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. [PDF]

ESMO Open
Pascual T, Villacampa G, Oliveira M, Escrivá-de-Romaní S, Pernas S, Paré L, Adamo B, Martínez E, Cortés J, Perelló A, Galan M, Melé M, Villanueva L, Gonzalez-Rodriguez M, Tolosa P, González-Farré B, Galván P, Canes J, Nuciforo P, Ferrero-Cafiero JM, González-Farré X, Villagrasa P, Prat A, Ciruelos E.   +23 more
europepmc   +1 more source